Medincell’s UZEDY® Achieves Major Milestones in Sales Growth

Author: Dylan Bailey Updated: 01-29-2025 09:50 AM

UZEDY® Sales Milestones in 2024

In a remarkable achievement, Medincell's UZEDY® has reached $117 million in total sales for the fiscal year of 2024, marking the first full year of its commercialization. This includes an impressive $43 million generated during the fourth quarter alone.

Comparative Sales Analysis

The recent figures represent a 17% increase from the previous Teva Pharmaceuticals' outlook, which projected sales of $100 million for 2024. The upward trajectory indicates robust demand for UZEDY® as both patients and healthcare providers embrace this innovative treatment.

Quarterly Breakdown of Sales

Sales for each quarter have shown strong performance:

Q1: $40 million
Q2: $35 million
Q3: $43 million

This steady growth showcases the product's increasing acceptance within the market.

Future Projections from Teva Pharmaceuticals

Looking ahead, the initial sales outlook for 2025 from Teva is promising, with projections estimating sales to reach as high as $160 million. This projection is significantly greater than the initial forecast for 2024, which was set at $80 million.

Royalties and Milestone Payments

Medincell is positioned to benefit from this growth through mid- to high-single digit royalties on all sales. Additionally, the company is eligible for up to $105 million in commercial milestone payments, further enhancing its revenue potential as UZEDY® continues to perform well.

Olanzapine Long-Acting Injectable: Next Steps

Medincell is also preparing for the filing and launch of its Olanzapine Long-Acting Injectable, known as TEV-749 / mdc-TJK. The company anticipates the last patient visit of its Phase 3 pivotal trial to occur soon, with long-term safety data expected to be released in the second quarter of 2025.

Regulatory Steps Ahead

The New Drug Application (NDA) submission is anticipated in the second half of 2025, a significant step towards bringing this treatment to the market, potentially expanding Medincell's therapeutic offerings.

About Medincell: A Leader in Biopharmaceuticals

Medincell is an innovative biopharmaceutical company focused on developing long-acting injectable treatments. Their mission includes improving medication adherence, enhancing treatment effectiveness, and reducing environmental impact. Medincell's proprietary BEPO technology allows for the controlled delivery of active ingredients, ensuring that patients receive therapeutic levels over extended periods from just a small injection.

Global Reach and Local Presence

With its headquarters in Montpellier, the company has established a diverse workforce of over 140 employees from more than 25 different nationalities, representing a significant global perspective in its research and development efforts.

Frequently Asked Questions

What is UZEDY® and its significance?

UZEDY® is a long-acting injectable treatment for schizophrenia approved by the FDA, and its success reflects Medincell's innovative approach in the biopharmaceutical sector.

What are the sales expectations for 2024?

Sales for UZEDY® are projected to reach $117 million for 2024, with strong quarterly performance demonstrating high patient acceptance.

What is the outlook for 2025 sales?

Teva's initial outlook for 2025 anticipates UZEDY® sales to grow to around $160 million, indicating continued market expansion.

When can we expect the next regulatory submission for Olanzapine?

The NDA submission for Olanzapine Long-Acting Injectable is expected in the second half of 2025 following successful clinical trials.

How does Medincell plan to use the projected royalties?

Medincell aims to utilize the projected royalties for further research, enhancing their product portfolio, and sustaining their growth in the biopharmaceutical market.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.